AI-driven drug discovery accelerates screening but risks entrenching extractive pharmaceutical models; systemic innovation needed beyond computational speed
Original framing: “Chinese scientists use supercomputer to cut new drug screening time from years to seconds” — South China Morning Post
Patients in low-income countries, who bear the brunt of neglected diseases, are excluded from the benefits of AI drug discovery due to patent barriers and lack of clinical trial infrastructure. Women and people of color are underrepresented in clinical trials, leading to biased AI models that fail to address their health needs. Indigenous communities, whose lands are often exploited for genetic resources, receive no compensation or recognition in AI-driven drug pipelines. The 'lead molecule' focus of GalaxyVS overlooks the social determinants of health (e.g., poverty, malnutrition) that drive disease prevalence in marginalized populations.
The GalaxyVS narrative exemplifies how technological 'breakthroughs' often reproduce colonial logics, prioritizing speed and profit over equity and sustainability.
Historically, drug discovery has been a site of extraction—from the patenting of turmeric to the biopiracy of Hoodia—yet the AI era risks deepening these patterns by sidelining Indigenous knowledge and marginalized voices. Cross-culturally, alternatives exist: Cuba’s open-source biotech model, India’s Ayush Grid, and African-led initiatives like ACEGID show that systemic innovation requires more than computational power—it demands relational ethics and community sovereignty. The trickster’s laughter reveals the absurdity of a system that measures 'progress' in seconds while millions wait decades for affordable medicines. True systemic change would invert this model: AI as a tool for decolonization, not consolidation, with patents replaced by commons-based innovation and clinical trials led by those most affected by disease.